Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PainchekASX:PCK 3-Year EPS without NRI Growth Rate is 3.50% as of Dec. 2025, which is 79% below its 10-year median of 16.80. The stock has 3 warning signs investors should review. Among 506 Healthcare Providers & Services companies, Painchek ranks worse than 62.06% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 3.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 13.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 12.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Painchek was 41.20% per year. The lowest was -7.90% per year. And the median was 16.80% per year.
Painchek (ASX:PCK) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Painchek 3-Year EPS without NRI Growth Rate Related Terms
ASX:PCK vs VEEV, BTSG, HQY: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, Painchek's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Painchek 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Painchek's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Painchek's 3-Year EPS without NRI Growth Rate falls into.
Painchek 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 3.50% mean?
Painchek (ASX:PCK) has a 3-Year EPS without NRI Growth Rate of 3.50% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Painchek and its competitors. This is 79% below median its historical median of 16.80. According to the industry distribution chart, Painchek ranks #314 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 62.1%.
Is Painchek's 3-Year EPS without NRI Growth Rate too high?
Painchek's current 3-Year EPS without NRI Growth Rate of 3.50% is 79% below median its 10-year median of 16.80. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.05. Painchek's value of 3.50% is 68.3% below this industry median. Based on the distribution chart, Painchek ranks #314 out of 506 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Painchek's 3-Year EPS without NRI Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #314 out of 506 companies for 3-Year EPS without NRI Growth Rate. This places Painchek in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.05. Painchek's value of 3.50% is 68.3% below this benchmark. While the company's 10-year median is 16.80 vs. the industry median of 11.05, Painchek has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.05, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Painchek's current 3-Year EPS without NRI Growth Rate of 3.50% is 68.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Painchek and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current 3-Year EPS without NRI Growth Rate is 3.50%, which is 79% below median its own 10-year median of 16.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.41, compared to a current price of A$0.10 — trading 75.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 3.50%, which is 79% below median its 10-year median of 16.80 and 68.3% below the Healthcare Providers & Services industry median of 11.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Painchek (ASX:PCK), the current 3-Year EPS without NRI Growth Rate is 3.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 
